Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents in USD of China SXT Pharmaceuticals, Inc. from Q1 2019 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
China SXT Pharmaceuticals, Inc. quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents history and change rate from Q1 2019 to Q1 2025.
  • China SXT Pharmaceuticals, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents for the quarter ending 31 Mar 2025 was $18.1M, a 50.1% increase year-over-year.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, YoY Quarterly Change (%)

China SXT Pharmaceuticals, Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents (USD)

Period Value YoY Chg Change % Date Report Filed
Q1 2025 $18.1M +$6.05M +50.1% 31 Mar 2025 20-F 31 Jul 2025
Q3 2024 $18.5M +$7.05M +61.5% 30 Sep 2024 6-K 28 Mar 2025
Q1 2024 $12.1M -$5.29M -30.5% 31 Mar 2024 20-F 31 Jul 2025
Q3 2023 $11.5M +$8.48M +285% 30 Sep 2023 6-K 28 Mar 2025
Q1 2023 $17.4M +$1.8M +11.6% 31 Mar 2023 20-F 31 Jul 2025
Q3 2022 $2.98M +$2.95M +9418% 30 Sep 2022 6-K 05 Apr 2024
Q1 2022 $15.6M +$2.21M +16.5% 31 Mar 2022 20-F 31 Jul 2025
Q3 2021 $31.3K -$10.3M -99.7% 30 Sep 2021 6-K 24 Feb 2023
Q1 2021 $13.4M +$6.07M +83.3% 31 Mar 2021 20-F 13 Aug 2024
Q3 2020 $10.4M +$2.03M +24.4% 30 Sep 2020 6-K 14 Jan 2022
Q1 2020 $7.29M -$2M -21.6% 31 Mar 2020 20-F 31 Jul 2023
Q3 2019 $8.32M 30 Sep 2019 6-K 28 Jan 2021
Q1 2019 $9.29M 31 Mar 2019 20-F/A 19 May 2023
* An asterisk sign (*) next to the value indicates that the value is likely invalid.